Skip to main content

Diabetes Mellitus: Pharmacotherapy-TZDs!

 PHARMACOTHERAPY: THIAZOLIDINEDIONES

  • Commonly referred to as TZDs or Glitazones,Thiazolidinediones have established a role in T2DM Therapy.

Mechanism of Action:

  • TZDs are known to increase insulin sensitivity by stimulating peroxisome proliferator-activated receptor gamma (PPAR-g). Stimulation of PPAR-g results in a number of intracellular and extracellular changes including increased insulin sensitivity and decreased plasma fatty acid levels.

Pharmacokinetics:

  • The onset of TZDs is delayed for several weeks and require up ton 12 weeks before maximum effects are observed.

Therapy:

  • As monotherapy, TZDs reduce FPG levels by around 60-70mg/dL and the effect of A1c is up to 1.5% reduction.


Clinical Uses:

  • Pioglitazone and Rosiglitazone increases HDL. Pioglitazone increases HDL by 5.2mg/dL Rosiglitazone increases HDL levels by 2-4mg/dL.
  • Pioglitazone decreases serum Triglycerides by an average of 51.9mg/dL. Rosiglitazone increases serum triglycerides.
  • Pioglitazone increases LDL levels by 12.3 mg/dL. Rosiglitazone increases LDL levels by 21.3mg/dL.


Adverse Effects:

  1. Fluid retention
  2. Edema
  3. Hepatotoxicity
  4. It is known that blood volume increases approximately 10% with these agents resulting in approximately 4-5% patients developing edema.


Contraindications:

These drugs are contraindicated in pt. with;

  • in situations in which increased fluid retention is detrimental such as heart failure.
  • Insulin therapy
  • Patients with a baseline alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of normal.
  • Increased rate of upper and lower limb fractures tends to occur with TZD therapy, hence patients with baseline fracture risk are contraindicated to receive TZDs.
  • Premenopausal women may begin to ovulate on TZD therapy and therefore counselling should be provided to all women capable to begin pregnant regarding this.
  • TZD is pregnancy category C drug, so proper precautions to avoid pregnancy should be used.
  •   In June 2011, the FDA alerted healthcare providers and patients that pioglitazone was found to be associated with an increased risk of bladder cancer after 1 year of therapy in ongoing epidemiological study.
  • As 2007 meta-analysis conducted by Nissen and colleagues, reported that non-significant increase in myocardial infarction with Rosiglitazone compared with other oral agents.
  • A subsequent prospective study found Rosiglitazone use to be associated with a non-significant increase in Myocardial infarction risk and non-significant reduction in stroke, but a trend towards increased cardiovascular risk in those patients with Ischemic stroke.
  • In May 2011, the FDA chose to restrict access and distribution of Rosiglitazone. It is currently only available through the Avandia-Rosiglitazone Medicines access Program for patients currently benefiting from the drug and in those who cannot achieve adequate disease management with other agents or who are not willing to use pioglitazone-containing medications after counselling with their healthcare provider.



Labels:

Comments

Post a Comment

Popular posts from this blog

Drug-Induced Ototoxicity!

 DRUG-INDUCED OTOTOXICITY What is drug Induced Ototoxicity? Drug-Induced ototoxicity can affect hearing (auditory or cochlear function0, balance (vestibular function) depending on the drug. Drugs of almost every class have been reported to produce tinnitus (sounds in ear), as have placebos. The following agents are associated with measurable changes in hearing or vestibular defect when administered systemically. 1. AMINOGLYCOSIDES: Aminoglycosides antibiotics can cause cochlear or vestibular toxicities. Cochlear toxicity: occurs as progressive hear loss, starting with highest tones and advancing to lower tones. Thus, considerable damage can occur before the patient recognizes it. S ymptoms of Vestibular damage : include;  Dizziness Vertigo Ataxia Both forms of ototoxicity are bilateral and potentially reversible, but permanent damage is common and can progress even after discontinuation of aminoglycosides. Clinically detectable ototoxicity in as many as 5% patients. Most amin...
Post a Comment
Read more

Diabetes Mellitus: Non-Pharmacological Therapy--MNT!

 NON PHARMACOLOGICAL THERAPY  MNT Glycemic Index Dietary supplements Weight measurements Physical Activity Psychological assessment Immunizations 1. MEDICAL NUTRITION THERAPY (MNT)  " Medical Nutrition Therapy (MNT) is a term used by the ADA to describe the optimal condition of caloric intake with other aspects of diabetes therapy (Insulin, Exercise, Weight loss)". The ADA has issued recommendations for three types of MNT: Primary prevention measures of MNT are directed at preventing or delaying the onset of type 2 Diabetes in high-risk individuals (obese or with pre-diabetes) by promoting weight reduction. Secondary prevention measures of MNT are directed at preventing or delaying-related complications in diabetic individuals by improving glycemic control. Tertiary prevention measures of MNT are directed at managing diabetes-related complications (cardiovascular disease, neuropathy) in diabetic individuals. Despite the popular notion, there is not any " Diabetic diet...
Post a Comment
Read more

Medical Emergency- Cardiac Arrest and Basic Life Support (BLS)!

  MEDICAL EMERGENCY- CARDIAC ARREST AND BASIC LIFE SUPPORT Definition: " Cardiac Arrest is a medical emergency requiring a systematic approach". Early recognition must be followed by prompt, effective application of Basic Life Support (BLS) techniques to sustain the patient until Advanced Life Support (ALS) capabilities are available. Management: The management of Cardiac Arrest is a 4-step approach: Recognition and Assessment BLS Advanced Cardiovascular Life Support (ACLS) Post-resuscitation Care 1. RECOGNITION AND ASSESMENT Verify that the respiration and circulation have ceased: Loss of consciousness Loss of functional ventilation (respiratory arrest or inadequate respiratory effort) Loss of functional perfusion (No pulse). 2. BASIC LIFE SUUPORT (BLS) The goal in cardiac arrest is the restoration of spontaneous circulation (ROSC). The first step towards achieving this ROSC goal is prompt initiation of BLS, where the goal is to rapidly and effectively perfuse the tissues wi...
Post a Comment
Read more